Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists Fine-Tune diagnostic tools for autonomic nervous system disorders

NCT ID NCT03648905

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 20 times

Summary

This study aims to improve how doctors test for autonomic failure, a condition where the body's automatic functions like blood pressure control don't work properly. Researchers will use advanced imaging, sweat tests, and skin biopsies in up to 89 adults with Parkinson's disease, multiple system atrophy, or related conditions. The goal is to make diagnoses more accurate and reliable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radioactive imaging agents (13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine, 18F-Dopamine)
What this could lead to
If successful, this could lead to better diagnostic tests for autonomic failure, helping doctors identify and manage conditions like Parkinson's disease more accurately.
What could go wrong
This is an observational study focused on improving tests, not testing a new treatment. It is small (89 participants) and may not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

89 people

The number who actually took part.

Started

Sep 2018

Finished

Jul 2026

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of patients with neurodegenerative CAF and patients with MSA. Comparison groups include control patients with iatrogenic CAF, patients with PD without OH (PD No OH), and Healthy Volunteers (HVs).

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITIERIA: Inclusion Critieria: Patients referred for orthostatic hypotension. This is the main subject cohort. * Previously studied and diagnosed with one of the forms of nOH or else newly accrued with a referral diagnosis of orthostatic hypotension, and * 18 years or older, and * Able to provide own consent to participate or have an existing Legally Authorized Representative (LAR). If a patient has already been diagnosed as having neurodegenerative CAF under NIH Clinical Protocol 03-N-0004, this satisfies the inclusion criteria for that patient. Previous enrollment in NIH Clinical Protocol 03-N-0004 is not required for enrollment in this study. We do plan to recruit participation into this study from NIH Clinical Protocol 03-N-0004, which has been closed. If a patient has been referred for OH, then the patient gives consent at the NIH Clinical Center (and therefore is accrued) and then has screening testing at the NIH Clinical Center to confirm that the OH is neurogenic. We anticipate that all patients referred for OH will be shown to have nOH upon screening testing at the NIH Clinical Center. At the time of screening, exclusionary abnormal laboratory test results (e.g., high serum creatinine indicating renal failure) may come to light, in which case they will be withdrawn from the study; however, the patient would have been accrued. Inclusion criteria: Control patients with iatrogenic CAF * Patients with heart transplants or pre- or post-bilateral endoscopic thoracic sympathectomies, and * 18 years or older, and * Able to provide own consent to participate. Inclusion criteria: Control patients with PD No OH: * Patients with PD and no OH who have (a) already been evaluated under other protocols of the AMS and are undergoing follow-up; (b) have already been evaluated under another intramural NINDS protocol; or (c) have cardiac symptoms, signs, or laboratory findings that in the opinion of the PI make it likely there is a cardiac sympathetic lesion, and * 18 years or older, and * Able to provide own consent to participate. Inclusion criteria: Healthy Volunteers: * Age 18 years or older, and * Able to provide own consent to participate. NIH employees may participate. There is no direct solicitation of employees/staff by supervisors. Co-workers will not solicit co-workers. NIH employees are required to abide by NIH Policy Manual 2300-630-3, "Leave Policy for NIH Employees Participating in NIH Medical Research Studies." EXCLUSION CRITIERIA: Patient Group Referred for Orthostatic Hypotension * A medical condition that in the judgment of the Principal Investigator would place the subject at substantially increased acute medical risk, or * A disqualifying condition such as: hepatic or renal failure, symptomatic congestive heart failure, severe anemia, psychosis, refractory ventricular arrhythmias, currently symptomatic coronary heart disease, cerebrovascular disease with current symptoms (e.g., recent transient ischemic attacks), diabetes, or * Secondary form of CAF, such as diabetic autonomic neuropathy, or * Being treated currently (within 2 weeks of anticipated protocol participation) with a medication known to interfere with the cell membrane norepinephrine transporter, which would obviate obtaining scientifically valid results (e.g., tricyclic antidepressant). * Condition that may cause difficulty or inability to insert a catheter into a vein, or * Unable to tolerate lying still for up to 1 hour during the procedures, or * Refusal to undergo certain procedures. These include: (1) IV catheter and blood drawing; (2) DNA extraction, storage, and analysis; (3) PET scanning; or * Unable to travel safely to the NIH CC, or * Lacking consent capacity, unless a Durable Power of Attorney (DPA) is in place, or * Pregnant or breast feeding, or * Subordinates of study investigators or relatives of the PI or AIs. Patient Control Group with Iatrogenic CAF or PD No OH * A medical condition which in the judgment of the Principal Investigator would place the subject at substantially increased acute medical risk, or * A disqualifying condition such as: hepatic or renal failure, symptomatic congestive heart failure, severe anemia, psychosis, refractory ventricular arrhythmias, currently symptomatic coronary heart disease, cerebrovascular disease with current symptoms (e.g., recent transient ischemic attacks), or diabetes, or * Being treated currently (within 2 weeks of anticipated protocol participation) with a medication that would obviate obtaining scientifically valid results (e.g., tricyclic antidepressant). * Condition that may cause difficulty or inability to insert a catheter into a vein, or * Unable to tolerate lying still for up to 1 hour during the procedures, or * Refusal to undergo certain procedures. These include: (1) IV catheter and (2) PET scanning, or * Unable to travel safely to the NIH CC, or * Lacking consent capacity, or * Pregnant or breast feeding, or * Subordinates of study investigators or relatives of the PI or AIs. Healthy Volunteer Group * A medical condition which in the judgment of the Principal Investigator would place the subject at substantially increased acute medical risk, or * A disqualifying condition such as: hepatic or renal failure, symptomatic congestive heart failure, severe anemia, psychosis, refractory ventricular arrhythmias, currently symptomatic coronary heart disease, cerebrovascular disease with current symptoms (e.g., recent transient ischemic attacks), diabetes, or * Being treated currently (within 2 weeks of anticipated protocol participation) with a medication that would obviate obtaining scientifically valid results (e.g., tricyclic antidepressant). * Condition that may cause difficulty or inability to insert a catheter into a vein, or * Unable to tolerate lying still for up to 1 hour during the procedures, or * Refusal to undergo certain procedures. These include: (1) IV catheter and (2) PET scanning, or * Unable to travel safely to the NIH CC, or * Lacking consent capacity, or * Pregnant or breast feeding, or * Subordinates of study investigators or relatives of the PI or AIs.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.